Anticancer agents and antitrypanosomiasis activity in mice

Of 303 compounds (66 active against cancer and 237 inactive against cancer) obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, 25 were found to be active against Trypanosoma rhodesien...

Full description

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 64; no. 2; p. 391
Main Authors Kinnamon, K E, Steck, E A, Rane, D S
Format Journal Article
LanguageEnglish
Published United States 01.02.1980
Subjects
Animals
Antineoplastic Agents - pharmacology
Drug Evaluation, Preclinical
Female
Male
Mice
Mice, Inbred ICR
Trypanocidal Agents
Trypanosomiasis - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Of 303 compounds (66 active against cancer and 237 inactive against cancer) obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, 25 were found to be active against Trypanosoma rhodesiense infections of ICR/Ha Swiss mice. Fifteen of these 25 compounds also had anticancer properties. The percentage of anticancer compounds found to have antitrypanosomiasis properties was 22.7. This percentage compares with 6% antitrypanosomiasis compounds among compounds selectecd by other methods.
ISSN:0027-8874
DOI:10.1093/jnci/64.2.391